FY2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)

Overview of Operating Results

For the cumulative third quarter period of the fiscal year ending March 2026, net sales totaled JPY 296.7 billion, representing a 0.1% increase YoY. Operating income was JPY 29.3 billion, a 2.6% decrease YoY. Ordinary income increased by 2.4% to JPY 30.3 billion, and net income attributable to owners of parent grew 3.4% to JPY 19.8 billion. By segment, the Life Science business saw sales increase by 14.6%, while the Chemicals business experienced declines in sales and earnings. The equity ratio stood at 55.4%, slightly down from the previous year.

Financial Position and Dividend

Total assets increased 2.8% YoY to JPY 558.4 billion, and net assets rose 3.7% to JPY 364.8 billion. Treasury shares at the end of the period stood at approximately 4.81 million shares, up from the previous year due to share buybacks. The annual dividend is forecasted at JPY 104, an increase of JPY 4 YoY. The full-year earnings forecasts anticipate net sales of JPY 415 billion, operating income of JPY 41.5 billion, and net income attributable to owners of parent of JPY 25.5 billion, all representing increases over the prior year.

Notable Items

A settlement was reached on December 31, 2025, regarding litigation involving a consolidated subsidiary, resulting in a special loss of JPY 1.033 billion. Additionally, based on the Board resolution on August 8, 2025, treasury stock acquisition is being conducted with an upper limit of 10 million shares and a maximum aggregate purchase amount of JPY 18 billion by May 31, 2026.